Compare Dover Corp (DOV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Pfizer Inc — how do they compare? Dover Corp trades at $188.59 (market cap $25.45B), while Pfizer Inc trades at $27.93 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.2× Dover Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Pfizer Inc for 158 Days on average.
| DOV | PFE | |
|---|---|---|
Market Cap | $25.45B | $158.56B |
Volume | 661,758 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $233.31 | $29.02 |
52-Week Low | $161.16 | $23.67 |
Typical Hold Time | 73 Days | 158 Days |
Enterprise Value | $26.95B | $210.06B |
Dividend Yield | 1.11% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.29, down 1.87% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and healthy profitability (13.48% net margin, 14.98% ROE). Recent acquisitions of Cloeren and Leistung expand manufacturing capabilities, while analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.
The outlook remains positive given Dover's Dividend King status, strategic acquisitions, and Wall Street support. Key risks include cyclical industrial exposure and recent negative cash flow trends. With no analyst sell ratings and technical indicators suggesting potential oversold conditions, the stock presents a compelling opportunity for long-term investors despite near-term bearish technical signals.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
